ARA-290 is a synthetic erythropoietin analogue peptide studied in preclinical immunology research for its role in innate repair receptor binding and anti-inflammatory signaling pathway analysis.
ARA-290 is a synthetic 11-amino acid peptide structurally derived from the helix B domain of erythropoietin (EPO), studied in preclinical immunology and tissue research. Unlike full-length erythropoietin, ARA-290 was designed to selectively engage a distinct receptor complex, making it a compound of interest for researchers studying tissue-protective signaling pathways independent of classical erythropoietin biology. Its short amino acid sequence and receptor-selective design have made it a useful comparative tool for researchers distinguishing tissue-protective signaling from the classical hematologic effects associated with erythropoietin.
ARA-290 is studied as an agonist of the innate repair receptor (IRR), a heteromeric complex composed of the erythropoietin receptor (EPOR) and the beta common receptor (CD131). This receptor assembly is distinct from the homodimeric EPOR complex responsible for classical erythropoietin's hematopoietic signaling. Research into IRR biology has focused on characterizing its tissue distribution and the downstream signaling cascades activated upon ARA-290 binding. Characterizing the relative expression of EPOR and CD131 across different tissue types has been an important step in defining which cell populations are capable of responding to IRR-selective ligands such as ARA-290.
A central area of ARA-290 research involves its proposed anti-inflammatory activity. In cultured immune cell models, IRR activation has been associated with modulation of NF-kB signaling, reduced pro-inflammatory cytokine output, and altered macrophage activation states. These findings have made ARA-290 a frequently referenced tool compound in preclinical studies examining innate immune signaling and inflammatory pathway regulation. Some studies have also examined ARA-290's effects on endothelial cell activation markers, extending its relevance to vascular inflammation research alongside its immune cell signaling profile.
For in-vitro research use only. Not for human or veterinary use.